Hite Christopher — SEC insider filings

SEC reporting owner CIK 1814238. 20 insider filings on record with FilingPulse; latest filed 2026-11-18.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2021-02-02 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Royalty Pharma plc (RPRX)EVP & Chairman, Partnering16—10 legs · 580,000 sh · $34,169,80314
ACCELERON PHARMA INC (XLRN)Director2——5
Kailera Therapeutics, Inc. (KLRA)Director1——1
Vera Therapeutics, Inc. (VERA)Director1——1

Insider filings — Hite Christopher

FiledFormIssuerReported transactionsSource
2026-11-184Royalty Pharma plc (RPRX)Sale (S): 100,000 @ $68.15EDGAR
2026-11-064Royalty Pharma plc (RPRX)Grant/award (A): 7,122 @ $0EDGAR
2026-09-244Royalty Pharma plc (RPRX)Sale (S): 96,073 @ $58.51 · Sale (S): 3,927 @ $58.93EDGAR
2026-08-194Royalty Pharma plc (RPRX)Sale (S): 100,000 @ $59.97 · Gift (G): 16,800 @ $0EDGAR
2026-08-074Royalty Pharma plc (RPRX)Grant/award (A): 11,002 @ $0EDGAR
2026-07-024Royalty Pharma plc (RPRX)Sale (S): 97,446 @ $56.50 · Sale (S): 2,554 @ $57.10 · Sale (S): 29,400 @ $56.44 · Sale (S): 600 @ $57.09EDGAR
2026-06-254Royalty Pharma plc (RPRX)Sale (S): 32,408 @ $54.11 · Sale (S): 117,592 @ $54.47EDGAR
2026-05-084Royalty Pharma plc (RPRX)Grant/award (A): 24,263 @ $0EDGAR
2026-04-204Kailera Therapeutics, Inc. (KLRA)Grant/award (A): 38,300 (derivative) @ $0EDGAR
2026-03-094Vera Therapeutics, Inc. (VERA)Grant/award (A): 24,937 (derivative) @ $0EDGAR
2026-02-134Royalty Pharma plc (RPRX)Grant/award (A): 26,626 @ $0EDGAR
2025-11-074Royalty Pharma plc (RPRX)Grant/award (A): 6,168 @ $0EDGAR
2025-08-084Royalty Pharma plc (RPRX)Grant/award (A): 3,696 @ $0EDGAR
2025-05-204Royalty Pharma plc (RPRX)Grant/award (A): 1,238,789 (derivative) @ $0EDGAR
2025-05-094Royalty Pharma plc (RPRX)Grant/award (A): 48,646 @ $0EDGAR
2025-02-184Royalty Pharma plc (RPRX)Conversion (C): 300,000 @ $0 · Conversion (C): 30,000 (derivative) @ $0EDGAR
2024-05-164Royalty Pharma plc (RPRX)Conversion (C): 300,000 @ $0 · Conversion (C): 30,000 (derivative) @ $0EDGAR
2021-11-224ACCELERON PHARMA INC (XLRN)Code (U): 930 · Disposition to issuer (D): 10,267 (derivative) · Disposition to issuer (D): 1,848 (derivative)EDGAR
2021-03-254Royalty Pharma plc (RPRX)Sale (S): 31,959 (derivative) @ $469.86EDGAR
2021-02-024ACCELERON PHARMA INC (XLRN)Grant/award (A): 930 @ $0 · Grant/award (A): 1,848 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1814238 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs